Exalenz Bioscience Ltd

Equities

EXEN

IL0011048688

Medical Equipment, Supplies & Distribution

Delayed TEL AVIV STOCK EXCHANGE Other stock markets			5-day change	1st Jan Change
- ^ILa	-.--%		+1.39%	+107.88%

2020	Meridian Bioscience, Inc. completed the acquisition of Exalenz Bioscience Ltd from Mori Arkin and others.	CI
2020	Meridian Bioscience, Inc. agreed to acquire Exalenz Bioscience Ltd from Mori Arkin and others for approximately ILS 170 million.	CI

Exalenz Bioscience Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2019

August 13, 2019 at 11:36 pm EDT

Exalenz Bioscience Ltd. announced earnings results for the second quarter ended June 30, 2019. For the second quarter, the company announced sales was USD 3.814 million compared to USD 3.390 million a year ago. Net loss was USD 222,000 compared to USD 1.103 million a year ago. Basic loss per share was USD 0.01 compared to USD 0.04 a year ago. For the half year, sales was USD 7.183 million compared to USD 6.653 million a year ago. Net loss was USD 888,000 compared to USD 1.977 million a year ago. Basic loss per share was USD 0.03 compared to USD 0.08 a year ago.

Latest news about Exalenz Bioscience Ltd

Meridian Bioscience, Inc. completed the acquisition of Exalenz Bioscience Ltd from Mori Arkin and others.	20-04-29	CI
Meridian Bioscience, Inc. agreed to acquire Exalenz Bioscience Ltd from Mori Arkin and others for approximately ILS 170 million.	20-02-18	CI
Exalenz Bioscience Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-13	CI
Exalenz Bioscience Receives Approval for Commercial Marketing in China for Its Breathid® HP Lab System	19-02-25	CI
Exalenz Bioscience Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	18-11-15	CI
Exalenz Bioscience Ltd Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2018	18-08-31	CI
Exalenz Bioscience Ltd. Announces BreathID®13C-methacetin Breath Test	18-07-10	CI
Exalenz Bioscience Appoints Roy Golan as President and Chief Financial Officer	18-04-30	CI
Exalenz Bioscience’s BreathID® Hp & BreathID Hp Lab Systems Receive FDA Clearance for Diagnosis of Helicobacter pylori Testing in Pediatric Patients	18-03-13	CI
Exalenz Bioscience Ltd Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017; Provides Earnings Guidance for the Year 2018 and Revenue Guidance for the Year 2019	18-03-12	CI
Exalenz Bioscience Announces Positive Clinical Trial Results for the Diagnosis of Clinically Significant Portal Hypertension in NASH Patients	18-01-24	CI
Exalenz Bioscience Ltd Launches Automated BreathID® Hp Lab Urea Breath Testing System For Helicobacter pylori Detection	17-08-17	CI
Exalenz Bioscience Plans For Nasdaq IPO	17-08-14	CI
Exalenz Bioscience Receives FDA Marketing Clearance for its Laboratory System in the United States	16-11-01	CI
Exalenz Bioscience Announces Collaboration with Galectin Therapeutics to Use BreathID to Monitor Patients with Cirrhosis Associated with NASH	15-08-03	CI
Exalenz Bioscience Ltd and Galectin Therapeutics, Inc. Receive FDA Approval for Joint Clinical Trial of Second-Stage of GR-MD-02	15-08-02	CI
Exalenz Bioscience Ltd Launches Clinical Study for Breath-Based Detection of Primary Liver Cancer	15-06-04	CI
Exalenz Bioscience Launches Additional Clinical Study of Breath-Based Diagnostic Test	15-05-06	CI
Exalenz Bioscience Ltd. Auditor Raises 'Going Concern' Doubt	15-02-25	CI
Exalenz Bioscience Launches Pivotal Study of Breath-Based Test to Diagnose Clinically Significant Portal Hypertension	14-10-21	CI
Exalenz Bioscience Expands its Breath Testing Technology into the Potential Billion Dollar Liver Diagnostic Market	14-05-21	CI
Exalenz Bioscience Appoints Gavin Doree as New Vice President of Sales	13-07-23	CI
Exalenz Bioscience Ltd Announces the Global Market Launch of the New BreathID(R) Hp for Detection and Management of H. pylori	13-07-15	CI
Exalenz Bioscience Ltd Names Ted Foltyn as New VP of Worldwide Marketing and Business Development	13-06-24	CI
Exalenz Bioscience Ltd Announces Consolidated Earnings Results for the Year Ended December 31, 2012	13-03-18	CI

Chart Exalenz Bioscience Ltd

Duration

Period

More charts

Company Profile

Exalenz Bioscience Ltd is an Israel-based company active in the medical sector. It develops and commercializes advanced systems that extract vital information for diagnostics from subtle changes in the patient's exhaled breath. Its core technology enables medical specialists to identify and manage specific digestive and liver conditions. The Company's product, the BreathID System, is used for assessment and monitoring of functional diseases of the liver and gastrointestinal tract. The BreathID System is mobile and can be operated in any clinical setting. The Company conducts ongoing research in collaboration with clinical and industrial partners in the United States, Europe, Asia, and Israel.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
EXALENZ BIOSCIENCE LTD	+107.88%	45.97M
ABBOTT LABORATORIES	-2.92%	185B
MEDTRONIC PLC	-3.80%	105B
BECTON, DICKINSON AND COMPANY	-5.48%	66.59B
DEXCOM, INC.	+11.22%	54.66B
CENCORA, INC.	+16.74%	47.78B
HOYA CORPORATION	+3.60%	41.26B
WEST PHARMACEUTICAL SERVICES, INC.	+4.56%	26.95B
METTLER-TOLEDO INTERNATIONAL, INC.	+1.64%	26.37B
TERUMO CORPORATION	+12.92%	24.8B

Other Medical Equipment, Supplies & Distribution